NCT05707676 (MEETCD8-001) is a Phase 1 clinical trial of LB4330 in Solid Tumor, sponsored by L & L Bio Co., Ltd., Ningbo, China.

Who is sponsoring NCT05707676?

NCT05707676 is sponsored by L & L Bio Co., Ltd., Ningbo, China.

What drugs are being tested in NCT05707676?

Interventions in NCT05707676: LB4330.

What condition does NCT05707676 study?

NCT05707676 studies Solid Tumor.

Is NCT05707676 still recruiting?

NCT05707676 is currently terminated. Last updated 11 September 2025.

Last reviewed 2025-09-11 · How we verify

NCT05707676: MEETCD8-001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）

Terminated Phase 1 Last updated 11 September 2025

What this trial tests

Phase 1 trial testing LB4330 in Solid Tumor in 40 participants. Terminated before completion.

Timeline

30 November 2022

Primary endpoint
20 December 2024

20 December 2024

Quick facts

Lead sponsor	L & L Bio Co., Ltd., Ningbo, China
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	30 November 2022
Primary completion	20 December 2024
Estimated completion	20 December 2024
Sites	1 location across China

Drugs / interventions tested

LB4330 — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

L & L Bio Co., Ltd., Ningbo, China — full company profile →

Who can join

Adults 18 to 75, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I study designed to evaluate if LB4330, an anti-Claudin 18.2 and CD8 T cell activator fusion protein, is safe, tolerable and efficacious in participants with Advanced Solid Tumors

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Claudin18.2 in Advanced Gastric Cancer.
Inamoto R, Takahashi N, Yamada Y. · · 2023 · cited 25× · PMID 38136288 · DOI 10.3390/cancers15245742
Future Landscape of Anti-Claudin 18.2 Antibodies in Gastric Adenocarcinoma.
Covert WM, Rogers JE. · · 2025 · cited 3× · PMID 40136475 · DOI 10.3390/antib14010026
Expression and Targeted Application of Claudins Family in Hepatobiliary and Pancreatic Diseases.
Du F, Xie Y, Wu S, Ji M, et al · · 2024 · cited 3× · PMID 39345937 · DOI 10.2147/jhc.s483861

Verify or expand the search:

Other trials of LB4330

Trials testing the same drug.

NCT06468358 — A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · recruiting

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other L & L Bio Co., Ltd., Ningbo, China trials

Trials by the same sponsor.

NCT06468358 — A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · recruiting
NCT05357651 — A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001） · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05707676 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by L & L Bio Co., Ltd., Ningbo, China
Last refreshed: 11 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05707676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing